Lakefront Biotherapeutics (LKFT) Other Non Operating Income (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Other Non Operating Income for 11 consecutive years, with $16.8 million the latest figure, recorded in Q4 2025.

• Quarterly Other Non Operating Income fell 16.38% year-over-year to $16.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $76.4 million (down 24.94% YoY) and the FY2025 annual result came in at $51.4 million, down 49.44% from the prior year.
• Other Non Operating Income grew to $16.8 million in Q4 2025 per LKFT's latest filing, from $13.4 million in the prior quarter.
• Over the last five years, Other Non Operating Income for LKFT reached as high as $41.2 million in Q1 2021 and fell as low as -$75.6 million in Q4 2021.
• A 5-year average of $11.6 million and a median of $18.5 million in 2024 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2022 — Other Non Operating Income sank 109.67% — and 2023, when it soared 2650.0%.
• Year by year, Other Non Operating Income stood at -$75.6 million in 2021, then soared by 118.22% to $13.8 million in 2022, then surged by 95.04% to $26.9 million in 2023, then dropped by 25.0% to $20.1 million in 2024, then slipped by 16.38% to $16.8 million in 2025.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $16.8 million, $13.4 million, and $20.1 million for Q4 2025, Q1 2025, and Q4 2024 respectively.